

Drug resistant models

- Comprehensive portfolio of drug resistant models
- 10+ cancer types
- 25+ key targets
- 30+ leading drugs
- 100+ resistant models
- 1,000+ validation data

Wide range of drug resistant models established in multiple strategies



Acquired resistance in tumor-bearing mice



Acquired resistance in cell culture



Engineered cell lines with reported mutations




PDX based on clinical resistant patients

Our experience and expertise focused on drug resistance

- Collaboration with **100+** clients across the world to develop combinatory or next-generation therapeutic strategies
- **20+** experts dedicated to this platform with deep understanding in drug resistance biology
- Multidisciplinary **bioinformatics** and **analytical** capabilities enabling clear and in-depth understanding of mechanisms
- **400+** projects delivered with high quality and efficient timeline.
- **10+** years experience in cancer pharmacology
- A comprehensive range of models representing **clinically relevant** mechanisms of resistance

Potential strategies for overcoming drug resistance

- Supporting next-generation targeted drug discovery overcoming the acquired resistance, e.g., 4th generation EGFR TKI evaluation in Osimertinib resistant models.
- Exploring potential combination strategies to maximize the therapeutic efficacy and overcome the drug resistance, e.g., Sotorasib (AMG510) combined with SHP2 targeted agents in Sotorasib resistant models.
- Differentiating from the existing drug portfolio. For example, novel antibody-drug conjugates (ADCs) or new modalities in DS-8201 or T-DM-1 resistant models



Contact us

Technical: Pharmacology-BD-Translation@wuxiapptec.com
 BD USA: mahnaz_arjomand@wuxiapptec.com
 BD EU/UK/Israel: dave_madge@wuxiapptec.com





BD China: xu_longji@wuxiapptec.com
 BD Japan: fumio_itoh@wuxiapptec.com
 BD Korea: sycho@wuxiapptec.com

Case study: acquired resistant model of KRAS G12C inhibitor




Resistance phenotype

 *in vivo* models

 *in vitro* assays



Resistance mechanism



Overcoming resistance

 Small molecule inhibitors

 Immune checkpoint inhibitors

